ZA202105654B - Method of producing a binder-toxin fusion protein in a plant cell or a whole plant - Google Patents

Method of producing a binder-toxin fusion protein in a plant cell or a whole plant

Info

Publication number
ZA202105654B
ZA202105654B ZA2021/05654A ZA202105654A ZA202105654B ZA 202105654 B ZA202105654 B ZA 202105654B ZA 2021/05654 A ZA2021/05654 A ZA 2021/05654A ZA 202105654 A ZA202105654 A ZA 202105654A ZA 202105654 B ZA202105654 B ZA 202105654B
Authority
ZA
South Africa
Prior art keywords
binder
producing
fusion protein
plant
toxin fusion
Prior art date
Application number
ZA2021/05654A
Other languages
English (en)
Inventor
Bertrand Magy
Max Houry
Original Assignee
Atb Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atb Therapeutics filed Critical Atb Therapeutics
Publication of ZA202105654B publication Critical patent/ZA202105654B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/13—Immunoglobulins specific features characterized by their source of isolation or production isolated from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA2021/05654A 2019-02-18 2021-08-05 Method of producing a binder-toxin fusion protein in a plant cell or a whole plant ZA202105654B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19157839 2019-02-18
PCT/EP2020/054263 WO2020169620A1 (en) 2019-02-18 2020-02-18 Method of producing a binder-toxin fusion protein in a plant cell or a whole plant

Publications (1)

Publication Number Publication Date
ZA202105654B true ZA202105654B (en) 2023-04-26

Family

ID=65717705

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2021/05654A ZA202105654B (en) 2019-02-18 2021-08-05 Method of producing a binder-toxin fusion protein in a plant cell or a whole plant

Country Status (11)

Country Link
US (1) US20220090113A1 (cg-RX-API-DMAC7.html)
EP (2) EP3927831B1 (cg-RX-API-DMAC7.html)
JP (2) JP7150999B2 (cg-RX-API-DMAC7.html)
KR (1) KR102398485B1 (cg-RX-API-DMAC7.html)
CN (2) CN115925972A (cg-RX-API-DMAC7.html)
BR (1) BR112021016348A2 (cg-RX-API-DMAC7.html)
CA (1) CA3128793C (cg-RX-API-DMAC7.html)
ES (1) ES3055338T3 (cg-RX-API-DMAC7.html)
IL (1) IL285719B (cg-RX-API-DMAC7.html)
WO (1) WO2020169620A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202105654B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102398485B1 (ko) * 2019-02-18 2022-05-16 에이티비 테라퓨틱스 식물 세포 또는 식물 전체에서 결합제-독소 융합 단백질의 생산 방법
US20230203108A1 (en) * 2020-05-28 2023-06-29 Chugai Seiyaku Kabushiki Kaisha Improved granzyme b variant
WO2022038152A1 (en) 2020-08-17 2022-02-24 Atb Therapeutics Recombinant immunotoxin comprising a ribotoxin or rnase
EP4328243A4 (en) * 2021-04-20 2025-05-21 Korea University Research and Business Foundation Asymmetric antibody with improved cytotoxicity against cancer cell
CN117440971A (zh) * 2021-04-20 2024-01-23 高丽大学校产学协力团 具有提高的癌细胞杀灭功效的非对称抗体
WO2023156634A1 (en) 2022-02-17 2023-08-24 Atb Therapeutics Recombinant immunotoxin comprising a ribosome inactivating protein
CN114605556B (zh) * 2022-03-10 2023-04-14 南开大学 一种增强植物根系募集功能细菌的融合蛋白及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6140075A (en) 1994-07-25 2000-10-31 Monsanto Company Method for producing antibodies and protein toxins in plant cells
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
CA2454048C (en) * 2001-07-17 2011-05-03 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ATE306810T1 (de) 2002-03-05 2005-11-15 Artemis Pharmaceuticals Gmbh Durch inzucht erzeugte von embryonalen stammzellen abgeleitete mäuse
JP2006507800A (ja) 2002-06-07 2006-03-09 ラージ・スケール・バイオロジー・コーポレイション 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム
AR056142A1 (es) 2005-10-21 2007-09-19 Amgen Inc Metodos para generar el anticuerpo igg monovalente
US20090148904A1 (en) * 2007-11-13 2009-06-11 Mayfield Stephen P Production of cytotoxic antibody-toxin fusion in eukaryotic algae
EP2113255A1 (en) * 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
US9586996B2 (en) 2010-04-30 2017-03-07 Esperance Pharmaceuticals, Inc. Lytic-peptide-Her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
PH12012502433A1 (en) 2010-06-09 2013-02-11 Du Pont Regulatory sequences for modulating transgene expression in plants
CN111363047A (zh) 2013-03-12 2020-07-03 分子模板公司 用于引起细胞内化的cd20结合免疫毒素及其使用方法
WO2016187585A1 (en) * 2015-05-20 2016-11-24 Viventia Bio Inc. Deimmunized linker and methods of use
CN105753986B (zh) * 2016-04-24 2019-12-10 赵磊 一类抗cd20靶向抗体及用途
KR102398485B1 (ko) * 2019-02-18 2022-05-16 에이티비 테라퓨틱스 식물 세포 또는 식물 전체에서 결합제-독소 융합 단백질의 생산 방법

Also Published As

Publication number Publication date
JP2022518614A (ja) 2022-03-15
JP2022176933A (ja) 2022-11-30
IL285719A (en) 2021-10-31
CN113728107B (zh) 2022-06-24
IL285719B (en) 2022-07-01
CA3128793A1 (en) 2020-08-27
ES3055338T3 (en) 2026-02-11
BR112021016348A2 (pt) 2021-11-23
EP4733324A3 (en) 2026-06-24
JP7728587B2 (ja) 2025-08-25
KR20210120051A (ko) 2021-10-06
CN115925972A (zh) 2023-04-07
EP3927831A1 (en) 2021-12-29
WO2020169620A1 (en) 2020-08-27
US20220090113A1 (en) 2022-03-24
EP3927831C0 (en) 2025-11-12
EP3927831B1 (en) 2025-11-12
KR102398485B1 (ko) 2022-05-16
JP7150999B2 (ja) 2022-10-11
EP4733324A2 (en) 2026-04-29
CN113728107A (zh) 2021-11-30
CA3128793C (en) 2023-02-28

Similar Documents

Publication Publication Date Title
IL276597A (en) A method for producing a low antigenic cell
IL285719A (en) Method of producing a binder-toxin fusion protein in a plant cell or a whole plant
IL280387A (en) A method for producing cells derived from dental pulp
SG11202005433SA (en) Scaffolding material for stem cell cultures and stem cell culture method using same
HUP1800376A2 (hu) Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer
EP3587559A4 (en) MANUFACTURING METHOD FOR ARTIFICIAL PLURIPOTENT STEM CELLS
IL287318A (en) Materials and methods for the production of proteins
IL277467A (en) A method for producing natural killer cells
PT3835415T (pt) Método para produção de células positivas para cd3
PL3999316T3 (pl) Sposób i układ do wytwarzania trójwymiarowej porowatej struktury
EP3950711A4 (en) CELL CONSTRUCT AND METHODS OF PRODUCTION
EP3279311A4 (en) Artificial skin culture container and method for producing artificial skin using same
PT3722504T (pt) Material de enchimento de superfícies de relva artificial e processo para o seu fabrico
EP4410965A4 (en) T LYMPHOCYTE PRODUCTION PROCESS
ZA202005741B (en) Methods for improving cell viability in a production bioreactor
EP3993010A4 (en) LAYER BODY AND METHOD FOR PRODUCING A LAYER BODY
EP3778902A4 (en) Cell production method
SG11202101902QA (en) Biomaterial comprising adipose-derived stem cells and gelatin and method for producing the same
EP3770249A4 (en) METHOD OF THREE-DIMENSIONAL CULTIVATION OF PLURIPOTENT STEM CELLS
EP3903991A4 (en) THREE-DIMENSIONAL LAMINATION METHOD AND OBJECT HAVING A THREE-DIMENSIONAL SHAPE
SG11202011845XA (en) Production method for culture supernatant preparation
HUE058887T2 (hu) Háromfókuszú szemészeti mûlencse és eljárás annak elõállítására
EP3254240A4 (en) System and method for using artificial intelligence in making decisions
SG10201806694VA (en) Solar cell and manufacturing method therefor
NO20191481A1 (en) Energy production and storage system and method